Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Sumitomo Pharma America, Inc.172 enrolled

Overview

This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.

This is an 18-week, double-blind, randomized, historical control, multicenter study with gradual conversion to monotherapy in subjects with partial onset seizures who are not well controlled by current AEDs. The 18 week double-blind treatment period consists of a 2-week titration period, 6-week taper or conversion period, and a 10-week monotherapy period. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

172

Conditions

Epilepsy

Interventions

Eslicarbazepine acetate 1600 mgDRUG

1600 mg once per day

Eslicarbazepine acetate 1200 mgDRUG

1200 once per day

Eligibility

Sex: ALLMin age: 16 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of partial epilepsy as defined in the Classification of Seizures of the International League Against Epilepsy (ILAE) (simple partial seizures with observable motor component, or complex, with or without secondary generalization) * Medical history of seizures; * Absence of confounding factors (pseudoseizures, syncope); * Documented EEG recording (done within 5 years prior to screening) consistent with focal onset epilepsy * Documented CT or MRI scan conducted within 10 years prior to screening, showing the absence of a structural abnormality (eg, tumor or malformation) * ≥ 4 partial onset seizures during the 8 weeks prior screening with no 28-day seizure free period * Stable treatment with 1-2 AEDs during the last 4 weeks prior to screening * Subjects must have the ability to comprehend the informed consent form and be willing to provide informed consent. For subjects who are unable to comprehend the written consent, a witness/caregiver who is able to describe and provide an understanding of the informed consent to the subject must sign the consent form on behalf of the subject. * Subjects must give written informed consent prior to participation in the study. For subjects \<18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. Subjects of Asian ancestry are required to give written informed consent for genotyping. All subjects must sign a HIPAA Form. All females of child bearing potential must also sign the "Women of Childbearing Potential" Addendum. * A female subject is eligible to enter and participate in the study if she is of: * Non-childbearing potential (ie, physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal); * Child-bearing potential (all females ≤65 years of age), has a negative pregnancy test at screening and agrees to satisfy contraception requirements Exclusion Criteria: * Subjects with only simple partial seizures without a motor component * Presence of generalized seizure syndromes (eg, juvenile myoclonic epilepsy or Lennox-Gastaut syndrome) * History of pseudo-seizures * Current seizures related to an acute medical illness * Seizures secondary to metabolic, toxic or infectious disorder or drug abuse * Status epilepticus within 2 years prior to screening * Seizures only occurring in a cluster pattern * Subjects taking 2 of the following sodium channel blocking AEDs: phenytoin, carbamazepine, oxcarbazepine, or lamotrigine * Subjects taking 2 AEDs with both being in the upper dose range (defined as approximately two-thirds of the defined daily dose) * Subjects taking more than 2 AEDs * Subjects with progressive structural central nervous system lesion or progressive encephalopathy * Psychiatric exclusion criteria * Medical exclusion criteria: known renal insufficiency (estimated creatinine clearance \[CrCL\]) \<60 mL/min based on serum creatinine using the Cockcroft-Gault formula * Clinical and laboratory exclusion criteria: Subjects of Asian ancestry who tests positive for the presence of the HLA-B\*1502 allele * Subjects who have been on benzodiazepines, phenobarbital, or primidone on a regular basis within 3 months prior to screening * Subjects taking antipsychotics, tricyclic antidepressants, anxiolytics, sedative hypnotics including non-benzodiazepines, central opioid agonists/antagonists, monoamine oxidase inhibitors (MAOIs) within at least 5 half lives (or for at least 2 weeks whichever is longer) prior to randomization * Subjects presently on felbamate or vigabatrin

Locations (62)

Outcomes

Primary Outcomes

Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method

Cumulative exit rate was defined as the proportion of subjects meeting at least one of the following five exit criteria over a 16-week study period (from start of AED taper/con. period (Wk 3) to end of double blind monotherapy period (Wk 18)).1.One episode of status epilepticus.2.One secondary gen. partial seizure (in subjects who did not have gen.seizures during 6 mo. prior to screening).3.A two fold increase in any consecutive 28 day seizure rate compared to the highest consecutive 28 day seizure rate during the 8 week baseline period. 4.A two fold increase in any consecutive 2 day seizure rate compared to the highest consecutive 2 day seizure rate during the 8 week baseline period. If the highest number of seizures in any consecutive 2 day period during the 8 week baseline was 1 then 3 seizures in a consecutive 2 day period was required to exit. 5.Worsening of seizures or increase in seizure frequency considered serious or requiring intervention as judged by the investigator

Time frame: From beginning of Week 3 to end of Week 18

Secondary Outcomes

Proportion (%) of Subjects That Are Seizure-free During the 10-week Double-blind Monotherapy Treatment Period.

Seizure-free subjects during the monotherapy period were determined as subjects who had seizure assessments during the monotherapy period, and did not have any seizures in the 10 weeks between Visits 6 and 9 (Weeks 9 through 18). Subjects who discontinued during this period were considered not seizure-free even if they were seizure-free at the time of discontinuation, i.e., to be considered seizure-free, subjects must complete the 10-week period without any seizures.

Time frame: Week 9 through 18

Percentage of Subjects Seizure-free During the Last 4 Weeks on Eslicarbazepine Acetate Monotherapy.

Percentage of participants that were Seizure-free during the last four weeks of monotherapy were determined as subjects who had seizure assessments during the 4 weeks between Visits 8 and 9 (Weeks 15 through 18), and did not have any seizures.

Time frame: Week 15 through 18

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Arizona Health Sciences Center

Tucson, Arizona, United States

Arkansas Neurology

Conway, Arkansas, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Kern County Neurological Medical Group, INC.

Bakersfield, California, United States

Neuro-Pain Medical Center

Fresno, California, United States

West Los Angeles VA Medical Center

Los Angeles, California, United States

Neurosearch II Inc.

Ventura, California, United States

Specialty Nuerology, PC

Englewood, Colorado, United States

Palm Springs Research Institute, Inc

Hialeah, Florida, United States

Miami Children's Hospital

Miami, Florida, United States

...and 52 more locations